Lung cancer is among the most common causes of
cancer-related mortality. It has a high mortality rate and resistance to
chemotherapy due to its high metastatic potential.
Naringenin, a bioactive compound identified in several fruits, displays anti-inflammatory and antitumor effects. Furthermore,
naringenin mitigates the migration of several human
cancer cell types. However, the effects of
naringenin on
lung cancer remain unclear. The current study investigated the mechanisms of
naringenin on the migration of
lung cancer A549 cells. The results indicate that significant alteration in A549 cell proliferation was observed in response to
naringenin (0-300 µM) treatment for 24 and 48 h. Furthermore, a dose-dependent migration inhibition of A549 in the presence of
naringenin was observed by healing and transwell migration assays. In addition, a zymography assay revealed that
naringenin exhibited a concentration-dependent inhibition of
matrix metalloproteinase (MMP)-2 and -9 activities. Furthermore,
naringenin also inhibited the activities of AKT in a dose-dependent manner. These observations indicated that
naringenin inhibited the migration of
lung cancer A549 cells through several mechanisms, including the inhibition of AKT activities and reduction of MMP-2 and -9 activities.